Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
- First Posted Date
- 2014-08-29
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT02228512
Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
- Conditions
- Interventions
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 6
- Registration Number
- NCT02212574
- Locations
- 🇺🇸
Ann and Robert H Lurie Children's Hospital of Chicago Hematology/Oncology, Chicago, Illinois, United States
🇺🇸Children's Hospital Colorado Center for Cancer & Blood Disorders, Aurora, Colorado, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan
- Conditions
- Interventions
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 140
- Registration Number
- NCT02162771
Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- South Plains Oncology Consortium
- Target Recruit Count
- 4
- Registration Number
- NCT02163356
- Locations
- 🇺🇸
Cook Children's Hospital, Fort Worth, Texas, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionBiological: BlinatumomabProcedure: Bone Marrow Aspiration and BiopsyProcedure: Computed TomographyProcedure: EchocardiographyDrug: DasatinibProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingDrug: MercaptopurineDrug: MethotrexateDrug: Methotrexate SodiumDrug: PrednisoneDrug: VincristineDrug: Vincristine SulfateProcedure: X-Ray Imaging
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT02143414
- Locations
- 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸John L McClellan Memorial Veterans Hospital, Little Rock, Arkansas, United States
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
- Conditions
- Acute Undifferentiated LeukemiaAcute Leukemia of Ambiguous LineageMixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise SpecifiedMixed Phenotype Acute LeukemiaMixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise SpecifiedAcute Bilineal LeukemiaAcute Biphenotypic LeukemiaRecurrent Mixed Phenotype Acute Leukemia
- Interventions
- First Posted Date
- 2014-05-12
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT02135874
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma
- Conditions
- Interventions
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 6
- Registration Number
- NCT02116959
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 125
- Registration Number
- NCT02114229
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
🇺🇸Lucille Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
- Conditions
- Adult T Acute Lymphoblastic LeukemiaAnn Arbor Stage II Adult Lymphoblastic LymphomaAnn Arbor Stage II Childhood Lymphoblastic LymphomaAnn Arbor Stage III Adult Lymphoblastic LymphomaAnn Arbor Stage III Childhood Lymphoblastic LymphomaAnn Arbor Stage IV Adult Lymphoblastic LymphomaAnn Arbor Stage IV Childhood Lymphoblastic LymphomaChildhood T Acute Lymphoblastic Leukemia
- Interventions
- Drug: CyclophosphamideDrug: BortezomibDrug: CytarabineDrug: DaunorubicinDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: DoxorubicinDrug: Doxorubicin HydrochlorideDrug: EtoposideDrug: Hydrocortisone Sodium SuccinateDrug: IfosfamideDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseRadiation: Radiation TherapyDrug: ThioguanineDrug: Vincristine SulfateDrug: Vincristine
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 847
- Registration Number
- NCT02112916
- Locations
- 🇺🇸
Covenant Children's Hospital, Lubbock, Texas, United States
🇺🇸UMC Cancer Center / UMC Health System, Lubbock, Texas, United States
🇦🇺Monash Medical Center-Clayton Campus, Clayton, Victoria, Australia
A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT02110069
- Locations
- 🇺🇸
Emory Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.